uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta Sells 28,341 Shares

uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta sold 28,341 shares of the firm’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $291,628.89. Following the completion of the sale, the chief executive officer now directly owns 651,454 shares of the company’s stock, valued at $6,703,461.66. This represents a 4.17 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

uniQure Stock Performance

Shares of NASDAQ:QURE opened at $12.09 on Thursday. The firm has a 50 day moving average of $14.69 and a 200 day moving average of $9.91. The company has a market capitalization of $589.30 million, a price-to-earnings ratio of -2.44 and a beta of 0.38. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18.

Hedge Funds Weigh In On uniQure

A number of large investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. grew its holdings in shares of uniQure by 9.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 969 shares during the last quarter. Tudor Investment Corp ET AL raised its position in shares of uniQure by 5.9% during the 4th quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company’s stock worth $438,000 after purchasing an additional 1,371 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of uniQure by 13.9% during the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock worth $217,000 after purchasing an additional 1,503 shares during the last quarter. Northern Trust Corp raised its position in shares of uniQure by 2.1% during the 4th quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock worth $1,688,000 after purchasing an additional 1,923 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of uniQure by 6.0% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company’s stock worth $1,253,000 after purchasing an additional 3,996 shares during the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

QURE has been the subject of several research analyst reports. Raymond James raised uniQure from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the company from $20.00 to $52.00 in a research note on Tuesday, December 10th. Leerink Partners boosted their target price on uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. Guggenheim restated a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. The Goldman Sachs Group upped their target price on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 12th. Finally, Wells Fargo & Company dropped their price target on uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $38.89.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.